Low Dose Clindamycin Shows High Success Rate for Joint Infections

Low-dose clindamycin achieves a two-year treatment success rate of roughly 82 percent in patients with prosthetic joint infections, Bioengineer.org reported. The findings come from a retrospective cohort study published in the journal BMC Infectious Diseases. [1]

According to Bioengineer.org, researchers tracked patients who received treatment between 2010 and 2022 at a single centre. The study evaluated patients who took clindamycin at a typical dose of 300 mg three times daily, administered either by itself or combined with rifampicin and other antibiotics. [1]

An infection occurs when pathogens invade tissues, multiply, and trigger a reaction from host tissues and toxins. Clindamycin serves as a potential alternative treatment when standard first-line drugs are unsuitable for a patient, Bioengineer.org noted. [1][4]

The study demonstrated that roughly four out of five patients achieved a two-year cure with the lower dosage. Bioengineer.org reported that the treatment proved to be both effective and well-tolerated among the patient cohort. [1]